Application of osimertinib to inhibitor for resisting novel coronavirus infection
The invention discloses an application of osimertinib to an inhibitor for resisting novel coronavirus infection. Through a drug targeted screening experiment, it is found that an anti-tumor drug namely the osimertinib can be combined with an amino acid site of an RBD structural domain of spike protein of a novel coronavirus (SARS-CoV-2), and the anti-virus effect is achieved by competitively inhibiting combination of the structural domain and a host cell ACE2 receptor. A true virus drug protection experiment proves that the drug can inhibit virus replication, and a pseudovirus infection experiment proves that the drug mainly targets SARS-CoV-2 spike protein to influence virus adsorption, so that the osimertinib can be used for treating novel coronavirus pneumonia..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 31. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ZHANG GUOLIANG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-12-31, Last update posted on www.tib.eu: 2022-08-20, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
CN113855677 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA01314202X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA01314202X | ||
| 003 | DE-627 | ||
| 005 | 20230504111922.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA01314202X | ||
| 035 | |a (EPA)CN113855677 | ||
| 035 | |a (EPA)78986726 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ZHANG GUOLIANG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of osimertinib to inhibitor for resisting novel coronavirus infection |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-12-31, Last update posted on www.tib.eu: 2022-08-20, Last updated: 2023-02-09 | ||
| 520 | |a The invention discloses an application of osimertinib to an inhibitor for resisting novel coronavirus infection. Through a drug targeted screening experiment, it is found that an anti-tumor drug namely the osimertinib can be combined with an amino acid site of an RBD structural domain of spike protein of a novel coronavirus (SARS-CoV-2), and the anti-virus effect is achieved by competitively inhibiting combination of the structural domain and a host cell ACE2 receptor. A true virus drug protection experiment proves that the drug can inhibit virus replication, and a pseudovirus infection experiment proves that the drug mainly targets SARS-CoV-2 spike protein to influence virus adsorption, so that the osimertinib can be used for treating novel coronavirus pneumonia. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LIU SHUYAN |4 aut | |
| 700 | 0 | |a ZHANG SU |4 aut | |
| 700 | 0 | |a ZHOU ZIYUAN |4 aut | |
| 700 | 0 | |a XIAO GUOHUI |4 aut | |
| 700 | 0 | |a LIANG WANXIN |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 31. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:31 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/78986726/publication/CN113855677A1?q=CN113855677 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2021 |b 31 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2021 |b 31 |c 12 | ||